arrow_back Back to App

Improved Access to Innovative Kidney Care Treatments in Medicare

This act aims to improve access to modern drugs and equipment for individuals with kidney diseases covered by Medicare. Changes include extended financial support for new therapies and improvements in how they are reimbursed, potentially leading to better treatment quality and more choices for patients. Additionally, the act seeks to ensure payment stability for dialysis facilities, which may impact the continuity of services.
Key points
Extended financial support for new renal dialysis drugs and biological products, potentially increasing their availability.
Introduction of permanent add-on payments for innovative drugs after initial support, encouraging the development of new therapies.
Facilitated access to innovative dialysis equipment and supplies, including for breakthrough devices with expedited review.
Changes to the definition of renal dialysis services, which may affect coverage for drugs treating co-occurring conditions.
Direct payments to providers of dialysis services under Medicare Advantage for innovative therapies.
Adjustments to payments for dialysis facilities to better reflect labor costs and ensure financial stability.
article Official text account_balance Process page
Introduced
Citizen Poll
No votes cast
Additional Information
Print number: 119_S_2730
Sponsor: Sen. Blackburn, Marsha [R-TN]
Process start date: 2025-09-08
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Kidney Care Access Protection Act

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 119_S_2730.

Which chamber initiated this legislation?

This legislation was initiated in the Senate.

When did the legislative process begin?

The process officially started on 2025-09-08.

What are the main provisions?

Key points include:

  • Extended financial support for new renal dialysis drugs and biological products, potentially increasing their availability.
  • Introduction of permanent add-on payments for innovative drugs after initial support, encouraging the development of new therapies.
  • Facilitated access to innovative dialysis equipment and supplies, including for breakthrough devices with expedited review.
  • Changes to the definition of renal dialysis services, which may affect coverage for drugs treating co-occurring conditions.
  • Direct payments to providers of dialysis services under Medicare Advantage for innovative therapies.
  • Adjustments to payments for dialysis facilities to better reflect labor costs and ensure financial stability.
What is the specific legal status?

The current status is Introduced.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Sen. Blackburn, Marsha [R-TN].

What is the latest detailed status?

The latest detailed status is: Introduced in Senate

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-23.

CATEGORIES

Health